Keyword Analysis & Research: sage stock


Keyword Analysis


Keyword Research: People who searched sage stock also searched

Frequently Asked Questions

Who buys Sage stock?

SAGE stock was acquired by a variety of institutional investors in the last quarter, including Cooper Financial Group, and State of Alaska Department of Revenue. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.

Do analysts agree on SAGE Therapeutics (Sage) stock's price target?

According to analysts' consensus price target of $70.63, Sage Therapeutics has a forecasted upside of 81.4% from its current price of $38.93. Sage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

What is the upside for SAGE Therapeutics'stock?

Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.

What are Wall Street's 1-year price targets for SAGE Therapeutics'stock?

17 Wall Street analysts have issued 1-year price objectives for Sage Therapeutics' stock. Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.

Search Results related to sage stock on Search Engine